Herbert Huettlin

from Wikipedia, the free encyclopedia
Herbert Hüttlin with the Hüttlin-Kugelmotor-Hybrid® (2014)

Herbert Hüttlin (born September 1, 1943 in Steinen ) is a German entrepreneur, developer of innovations in the pharmaceutical sector and the designer of the Hüttlin spherical motor .

Life

Hüttlin grew up in Steinen in southern Baden, where he still lives today and runs an international technology company. He is a trained flow engineer , pharmaceutical technologist and founder, managing director and sole shareholder of INNOJET Herbert Hüttlin. He is also the majority shareholder and Chairman of the Board of INNOMOT AG, which builds the prototype of the Hüttlin spherical motor and issues licenses. In the course of his professional career, he has produced a large number of international patents, the majority of which are used in practice. In the course of his career, he has received high honors and awards for his life's work in the field of pharmaceutical technology. For years he worked closely with the Albert Ludwigs University of Freiburg (pharmaceutical technology and biopharmacy) and other international chairs.

Hüttlin applied for more than 150 patents in 10-25 industrial countries each.

Hüttlin has been developing patents for high-efficiency combustion engines since 1991, which culminated in the development of the prototype of a spherical motor.

Hüttlin is married and has two grown children. He is a grandfather of two. Both his son Holger and his nephew Wolfgang, as well as his son-in-law Christian Ott, work closely with him.

Awards and honors

  • Dr. Rudolf Eberle Prize 1st Prize Winner (1993)
  • Award of an honorary doctorate (2000)
  • Admission by Lothar Späth to the Innovation Club TOP 100, category innovation success 2nd place (2008)
  • Shortlist for the Process Innovation Award in the pharmaceutical technology category (2008)
  • Another success in the Top 100 innovation competition, in the Top 5 in the innovation success category (2009)
  • 1st prize of the Process Innovation Award in the category of pharmaceutical technology / biotechnology (2009)
  • Another success in the Top 100 innovation competition (2010)